What is Zag Bio?
Zag Bio, headquartered in San Francisco, California, is a biotechnology firm at the forefront of cancer treatment innovation. The company is developing a novel platform that utilizes engineered bacteria to target solid tumors and stimulate an immune response. This approach aims to overcome the limitations of current immunotherapies by delivering therapeutic payloads directly to the tumor site, minimizing systemic side effects and maximizing efficacy. Zag Bio's technology represents a new frontier in oncology, leveraging synthetic biology to create living therapeutics designed to adapt to the tumor microenvironment and provide new options for patients with hard-to-treat solid tumors.
How much funding has Zag Bio raised?
Zag Bio has raised a total of $80M across 1 funding round:
Series A
$80M
Series A (2025): $80M with participation from Sanofi, ABBVIE, Regeneron Pharmaceuticals, JDRF T1D Fund, and Polaris Partners
Key Investors in Zag Bio
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation, focusing on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care.
ABBVIE
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges, focusing on immunology, oncology, neuroscience, and eye care.
Regeneron Pharmaceuticals
Regeneron is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases, utilizing advanced science and proprietary technologies for conditions such as cancer, eye diseases, and inflammatory disorders.
What's next for Zag Bio?
With this substantial enterprise-level funding and strategic investment, Zag Bio is poised to accelerate its preclinical development and advance its lead therapeutic candidates toward clinical trials. The capital infusion will likely support further research and development, expansion of the scientific team, and the necessary infrastructure to progress its engineered bacteria-based therapeutics. This financing marks a critical step in Zag Bio's mission to provide novel treatment modalities for challenging cancers.
See full Zag Bio company page
